Capricor Therapeutics, Inc.
CAPRNext catalyst
Deramiocel (CAP-1002)
Duchenne muscular dystrophy (upper limb function)
Get an email about CAPR's next catalysts
Track Capricor Therapeutics (CAPR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
FDA PDUFA Date Deramiocel
For Duchenne muscular dystrophy (upper limb function). BLA; extended from Aug 22 after a major amendment. Verified against the company announcement on 2026-10-16.
SourceUpcoming FDA decisions
How CAPR's past catalysts played out
Market Overview
Stock performance and key metrics
CAP-1002
Cardiosphere-Derived Cells
Duchenne Muscular Dystrophy
Deramiocel
Muscular Dystrophies
Deramiocel (CAP-1002)
Duchenne Muscular Dystrophy
CAP-2003
COVID-19 Cardiac
Cenderitide
Heart Failure
Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAP-1002 Cardiosphere-Derived Cells | Phase 3 | Duchenne Muscular Dystrophy | OrphanFast Track | - |
Deramiocel | Phase 3 | Muscular Dystrophies | - | - |
Deramiocel (CAP-1002) | Phase 3 | Duchenne Muscular Dystrophy | - | - |
CAP-2003 | Phase 2 | COVID-19 Cardiac | - | - |
Cenderitide | Phase 2 | Heart Failure | - | - |
Allogeneic Cardiosphere-Derived Cells (CAP-1002) | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Duchenne Muscular Dystrophy
2 drugs in this indication
Duchenne muscular dystrophy (DMD)
2 drugs in this indication
COVID-19 Cardiac
1 drug in this indication
cardiomyopathy in patients with Duchenne muscular dystrophy
1 drug in this indication
DMD
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Capricor Therapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 6 drug candidates in Capricor Therapeutics, Inc.'s (CAPR) pipeline across Phase 3, Phase 2. Its lead program is Deramiocel (CAP-1002) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Capricor Therapeutics, Inc.'s next FDA catalyst?β
Capricor Therapeutics, Inc.'s (CAPR) next tracked catalyst is a PDUFA date expected Nov 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CAPR biotech catalysts?β
Add CAPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Capricor Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
